12h agoSeeking AlphaBULLISH 64Earnings
Replimune Group GAAP EPS of -$0.54 beats by $0.21
Replimune Q2 earnings beat estimates, with cash rising to $307.8M and R&D costs falling.
Archived explainer. For the current picture see today's REPL page.
Why Is REPLIMUNE GROUP INC (REPL) Stock Up Today?
By the Top Tier Newswire AI Desk · October 28, 2026 at 2:26 PM ET · reviewed against 3 wire stories
REPLIMUNE GROUP INC (REPL) is up +21.42% in the latest session. Our newswire has captured 3 stories on REPL across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Replimune Group shares surged 21.42% to close at $15.85 on Tuesday. The primary driver was the company’s fiscal second quarter 2027 earnings report, which showed a GAAP loss per share of $0.54, beating the consensus estimate of $0.77.
What Happened
Replimune filed a Form 8-K with the SEC on October 28, 2026, disclosing its financial results. The company reported that cash balances rose to $307.8 million while research and development costs declined. This performance followed the recent commercial availability of TUDRIQEV in the United States for the treatment of unresectable advanced cutaneous melanoma. The stock had been relatively flat over the preceding eight sessions, moving from $13.10 to $13.04 before the announcement.
What The Data Shows
The stock opened the session at $13.08 and hit a low of $12.30 at 9:25 AM ET before rallying to a session high of $15.99 at 2:20 PM ET. Trading volume reached 3.1 million shares, which is 0.8 times the three-month daily average. The company has a market capitalization of $1.2 billion and remains unprofitable with a trailing twelve-month EPS of $3.15. The stock’s beta is 0.94, and it currently trades within its 52-week range of $1.50 to $16.33. On the day of the report, the stock printed 36 fresh 52-week highs and 6 fresh 52-week lows. Recent insider activity includes five sales totaling $1.0 million over the last 90 days, with no buys recorded. The most recent Form 4 filings show sales by CEO Sushil Patel and CFO Emily Luisa Hill in August 2026.
What To Watch
Investors will monitor the company’s coverage breadth and future guidance following the earnings release. The stock’s position near its 52-week high suggests continued momentum, though the lack of recent insider buying may temper expectations for near-term support.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
REPL by the numbers
Last: $15.85Session: +21.42%7 sessions: -0.46%Coverage: 3 stories / 3 sourcesAI sentiment: 55/100 (mixed)Mkt cap: $1.2B52w: $1.50 to $16.33
The headlines behind the move
12h agoSEC 8-KNEUTRAL 50General
Replimune Group, Inc. (REPL) files 8-K
Filed: 2026-10-28 AccNo: 0001104659-26-119354 Size: 272 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
12h agoStockTitanNEUTRAL 52Earnings
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on REPL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier REPL move explainers: 2026-10-28 · 2026-09-29 · 2026-09-11 · 2026-09-10